Profusa's biggest risks in the FY2024 10-K
- Profusa operates as a blank check company seeking an initial business combination, primarily in healthcare.
The risks most specific to Profusa
- Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
We may not be able to complete the Business Combination pursuant to the Merger Agreement. If we are unable to do so, we will incur substantial costs associated with withdrawing from the transaction and may not be able to find additional sources of financing to cover those costs
We may fail to complete the Business Combination under the Merger Agreement and incur substantial unrecoverable withdrawal and financing costs.
- Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination
Adverse changes in the directors and officers liability insurance market could make negotiating our business combination more difficult and expensive.
- Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
The ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target
High redemptions by public stockholders could prevent us from meeting minimum cash closing conditions required by potential business combination targets.
- Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate
We must complete our initial business combination within the required time frame or cease all operations and liquidate.
- Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
Any failure to meet the initial listing requirements of Nasdaq could result in an inability to list our common stock and warrants on Nasdaq and the obligation to comply with the “penny stock” rules and could affect the combined company’s cash position following the closing of an initial business combination
Failure to meet Nasdaq initial listing requirements could prevent listing and trigger penny stock rules.
- Risks Relating to our Management and Directors
Since our sponsor paid only approximately $0.005 per share for the founder shares, our officers and directors could potentially make a substantial profit even if we acquire a target business that subsequently declines in value
Our sponsor acquired founder shares for $0.005 per share, creating potential for substantial profit despite public share price declines.
- Risks Relating to Our Securities
If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $10.10 per share
Third-party claims could reduce trust account proceeds below $10.10 per share.
All 58 risk factors
Headings as the filing states them, in filing order.
Risks Relating to Our Search For, Consummation of, or Inability to Consummate, a Business Combination
- 01We may not be able to complete the Business Combination pursuant to the Merger Agreement. If we are unable to do so, we will incur substantial costs associated with withdrawing from the transaction and may not be able to find additional sources of financing to cover those costs
- 02Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination
- 03We may issue our shares to investors in connection with our initial business combination at a price that is less than the prevailing market price of our shares at that time
- 04If we seek stockholder approval of our initial business combination, our sponsor, officers and directors have agreed to vote in favor of such initial business combination, regardless of how our public stockholders vote
- 05Your only opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash, unless we seek stockholder approval of the business combination
- 06The ability of our public stockholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target
- 07The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or optimize our capital structure
- 08The ability of our public stockholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your stock
- 09We may not be able to complete our initial business combination within the prescribed time frame, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate
- 10If a stockholder fails to receive notice of our offer to redeem our public shares in connection with our business combination, or fails to comply with the procedures for tendering its shares, such shares may not be redeemed
- 11If the net proceeds of our initial public offering and the sale of the private placement warrants not being held in the trust account are insufficient to allow us to operate for at least the term of the combination period, we may be unable to complete our initial business combination
- 12We may seek acquisition opportunities in companies that may be outside of our management’s areas of expertise
- 13We are not required to obtain an opinion from an independent investment banking firm or from an independent accounting firm, and consequently, you may have no assurance from an independent source that the price we are paying for the business is fair to our company from a financial point of view
- 14We may have a limited ability to assess the management of a prospective target business and, as a result, may effect our initial business combination with a target business whose management may not have the skills, qualifications or abilities to manage a public company
- 15We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our sponsor, executive officers and directors which may raise potential conflicts of interest
- 16We may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability
- 17We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all
- 18Our management may not be able to maintain control of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business
- 19We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results
- 20Any failure to meet the initial listing requirements of Nasdaq could result in an inability to list our common stock and warrants on Nasdaq and the obligation to comply with the “penny stock” rules and could affect the combined company’s cash position following the closing of an initial business combination
- 21We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our stockholders do not agree
- 22We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination
- 23Because we must furnish our stockholders with target business financial statements, we may lose the ability to complete an otherwise advantageous initial business combination with some prospective target businesses
Risks Relating to the Post-Business Combination Company
- 24Because we are not limited to a particular industry or any specific target businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business’ operations
- 25We may issue notes or other debt securities, or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our stockholders’ investment in us
- 26If we effect our initial business combination with a company with operations or opportunities outside of the United States, we would be subject to a variety of additional risks that may negatively impact our operations
Risks Relating to our Management and Directors
- 27As a public company, we are required to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act and make an ongoing, formal assessment of the effectiveness of our internal controls over financial reporting
- 28Past performance by our management team may not be indicative of future performance of an investment in us
- 29We are dependent upon our executive officers and directors and their departure could adversely affect our ability to operate
- 30The officers and directors of an acquisition candidate may resign upon completion of our initial business combination. The loss of a business combination target’s key personnel could negatively impact the operations and profitability of our post-combination business
- 31Our executive officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination
- 32Our executive officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests
- 33Since our sponsor, executive officers and directors will not be eligible to be reimbursed for their out-of-pocket expenses if our business combination is not completed, a conflict of interest may arise in determining whether a particular business combination target is appropriate for our initial business combination
- 34Since our sponsor paid only approximately $0.005 per share for the founder shares, our officers and directors could potentially make a substantial profit even if we acquire a target business that subsequently declines in value
Risks Relating to Our Securities
- 35You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be forced to sell your public shares, rights, or warrants, potentially at a loss
- 36If third parties bring claims against us, the proceeds held in the trust account could be reduced and the per-share redemption amount received by stockholders may be less than $10.10 per share
- 37A provision of our warrant agreement may make it more difficult for us to consummate an initial business combination
- 38Our directors may decide not to enforce the indemnification obligations of our sponsor, resulting in a reduction in the amount of funds in the trust account available for distribution to our public stockholders
- 39Our stockholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares
- 40We may not hold an annual meeting of stockholders until after our consummation of a business combination and you will not be entitled to any of the corporate protections provided by such a meeting
- 41The warrants may become exercisable and redeemable for a security other than the shares of our common stock, and you will not have any information regarding such other security at this time
- 42The grant of registration rights to our initial stockholders and holders of our private placement warrants may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our common stock
- 43Our amended and restated certificate of incorporation authorizes the issuance of up to 100,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of undesignated preferred stock, par value $0.0001 per share
- 44Certain agreements related to our initial public offering may be amended without stockholder approval
- 45Our initial stockholders control a substantial interest in us and thus may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support
- 46We may amend the terms of the rights in a manner that may be adverse to holders of rights with the approval by the holders of at least 65% of the then outstanding rights
- 47We may amend the terms of the warrants in a manner that may be adverse to holders of public warrants with the approval by the holders of at least 65% of the then outstanding public warrants
- 48We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless
- 49Our rights and warrants may have an adverse effect on the market price of our common stock and make it more difficult to effectuate our initial business combination
- 50Provisions in our amended and restated certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management
- 51Provisions in our amended and restated certificate of incorporation and Delaware law may have the effect of discouraging lawsuits against our directors and officers
- 52Our warrants are accounted for as warrant liabilities and recorded at fair value upon issuance with changes in fair value each period reported in earnings, which may make it more difficult for us to consummate an initial business combination
General Risks
- 53We are a newly formed company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective
- 54If we are deemed to be an investment company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted, which may make it difficult for us to complete our business combination
- 55Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations
- 56A market for our securities may not develop, which would adversely affect the liquidity and price of our securities
- 57Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an acquisition
- 58Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss
Other Profusa 10-Ks
- FY2025 10-K risk factors78 risks77 new57 dropped1 reworded
Profusa completed its transition from a special purpose acquisition company to an operating medical device firm commercializing its Lumee Oxygen and Glucose Platform. The risk profile shifted entirely from business combination mechanics to clinical trial progress, Nasdaq listing compliance, going concern doubts, and heavy operational losses.
Filed Apr 15, 2026
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.